Research Applications
Interstitial Cystitis (Approved)
FDA-approved as Elmiron. Reduces bladder pain and urinary urgency/frequency in IC/BPS patients.
Osteoarthritis
TGA-approved in Australia for veterinary osteoarthritis. Human trials show chondroprotective effects.
Prion Diseases
Research suggests PPS may inhibit prion protein aggregation.
Mechanism of Action
PPS coats the damaged urothelium, restoring the protective GAG (glycosaminoglycan) layer that prevents irritating urinary solutes from penetrating to underlying nerve fibers. It also has anti-inflammatory (inhibits mast cell histamine release), anticoagulant (weak heparin-like activity), and fibrinolytic properties. In joints, PPS stimulates hyaluronic acid synthesis and inhibits degradative enzymes (MMPs, aggrecanases).
Biological Pathways
GAG layer restoration in bladder. Mast cell stabilization. MMP inhibition in cartilage. Hyaluronic acid synthesis stimulation. Weak antithrombin III-mediated anticoagulation.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsStability & Storage
Oral capsules (Elmiron 100 mg) store at room temperature. Injectable form (veterinary) at room temperature. Stable compound with 3+ year shelf life.
Side Effects & Precautions
GI effects (nausea, diarrhea, 4%), alopecia (4%), headache. Maculopathy (pigmentary retinal changes) identified with long-term use (>3 years) — requires ophthalmological monitoring. Mild anticoagulant effect — use caution with blood thinners.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
FDA-approved as Elmiron (1996) for interstitial cystitis. Box warning about maculopathy risk added. Available by prescription only. Not WADA-prohibited.






